Coronavirus Update: Novavax's $384m Is CEPI’s Biggest Vaccine Funding
Plus: Non-Coronavirus Trials Need To Re-Start, Says UK Sector
Pioneer of nanoparticle vaccine technology is latest to get financial backing from the foundation.
You may also be interested in...
Progress for two US-based companies in the race to develop a COVID-19 vaccine.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Phase III trial could lead to mid-2020 BLA filing to prevent seasonal influenza in adults 65 and older. Novavax also talked up the potential value of its adjuvant in COVID-19 vaccine development.